Last mentioned: Feb 26, 2026
ANI Pharmaceuticals and Amneal Pharmaceuticals are preparing to report Q4 2025 results, with investors focusing on rare disease expansion and biosimilar adoption. The broader earnings window also features updates from Fulgent Genetics and Alpha Metallurgical, highlighting a diverse landscape of diagnostic shifts and commodity pricing.
ANI Pharmaceuticals and Amneal Pharmaceuticals are preparing to report Q4 2025 results, with investors focused on the growth of high-margin specialty products and biosimilar pipelines. These reports will serve as a bellwether for the generic-to-specialty pivot currently reshaping the mid-cap pharmaceutical landscape.
ANI Pharmaceuticals and Amneal Pharmaceuticals are preparing to report Q4 2025 results, with ANI expected to show significant double-digit growth in both revenue and earnings. These reports will provide a critical pulse check on the specialty generics market and the impact of recent portfolio expansions.